摘要
目的观察奥扎格雷钠治疗急性脑梗死的临床疗效和安全性。方法采用随机对照方法将178例急性脑梗死患者分为治疗组(奥扎格雷钠组)和对照组,两组分别在治疗前和治疗后7 d、14 d进行神经功能缺损评分、临床疗效评定并测定血浆纤维蛋白原(FIB)和D-二聚体等指标。结果与对照组比较,治疗组患者神经功能缺损评分的降低和临床疗效的改善差异均有显著性(P<0.05);治疗组治疗后7 d、14 d血浆FIB的浓度降低,治疗后7 dD-二聚体的浓度增加,14 dD-二聚体的浓度降低,差异具有显著性(P<0.05)。结论奥扎格雷钠能够降低纤维蛋白原,改善急性脑梗死患者的神经功能缺损,临床疗效显著。
Aim To investigate the effect of ozagrel sodium on acute cerebral infarction and its influence on fibrinogen and plasma D-dimer content.Methods 178 patients with acute cerebral infarction were randomly divided into control group and treatment group.The patients in control group were treated with fleabane,while the patients in treatment group were treated with ozagrel sodium and fleabane.The neurologic impairment score and was evaluated the content of fibrinogen and plasma D-dimer pre-and post-therapy 7th,14th was examined and compare the clinical treatment effects.Results Both the neurologic impairment score and the clinical treatment effect were significantly different（P〈0.05）.And the descent of FIB in treatment group was conspicuous as well as the change of plasma D-dimer,compared with the control group.Conclusion The clinical effect of ozagrel on acute cerebral infarction was overt by decreasing FIB and improving the neurologic impairment score.
出处
《安徽医药》
CAS
2009年第4期425-427,共3页
Anhui Medical and Pharmaceutical Journal
基金
科技部创新基金(No07C26224421831)
关键词
奥扎格雷钠
急性脑梗死
治疗
sodium ozagrel
acute cerebral infarction
therapy
